… can seem gradual. Trials go through detailed procedures to get approval, recruit participants and begin. Recently, … therapy forward in the drug development pipeline. NILO-PD: Completed recruitment of Phase II nilotinib trial for …

… Foundation for Parkinson’s Research announced $710,000 in total funding to seven research teams for projects … and clinicians alike — is the significant variability in how the disease manifests itself from patient to patient,” … will focus on determining predictive factors for reaching a common neuroprotective clinical trial endpoint — time to …

… nursing home residents, and it is critical for lawmakers to determine what needs to be done to protect these … significantly higher infection and mortality rate among communities of color, specifically Black, Hispanic, American … to support several bills to ensure no cost, regular testing for residents and personnel; supply of personal …

… less vulnerable than the allocortex (fewer than six layers) to alpha-synuclein pathology. No one knows the reason for this striking difference. However, we have found that the neocortex is more resistant … be knocked down to test the hypothesis that neocortex becomes more vulnerable to alpha-synuclein toxicity when …

… Beth Hochstein poses with her two children, Max and Sarah Editor's Note: With her Dance Party for Parkinson’s Zumbathon Charity Event coming up on Saturday, April 5 in New York City, we asked … a Dance for Parkinson's class with a friend and realized how great dance is for people living with PD. What I …

… alpha-synuclein over production-a well-known causative factor in familial form PD. This proposed study is designed to … type and genetically modified. The modified microRNA will completely match that risk genetic variation in order to … levels of alpha-synuclein in postmortem brain tissue. However, limited numbers of brain samples made the finding …